Dronabinol

Medical Uses of Dronabinol:

• Used for appetite stimulation in HIV/AIDS and cancer patients.
• Treats chemotherapy-induced nausea and vomiting.
• Demonstrated analgesic efficacy in chronic pain studies.
• Potential in treating cannabis addiction.
• Studies suggest potential in obstructive sleep apnea treatment.

Regulatory and Legal Aspects:

• FDA approval in 1985 and rescheduling from Schedule I to II in 1986.
• Commission on Narcotic Drugs decision in 1991 facilitated medical use.
• Rescheduled from Schedule II to III in the US in 1999.
• WHO recommendation to transfer THC to Schedule IV in 2003.
• Efforts to reschedule cannabis have not succeeded.

Comparisons with Medical Cannabis:

• Female cannabis plants contain dronabinol and other cannabinoids.
• Differences in efficacy and onset of action compared to medical cannabis.
• Clinical trials show equal efficacy between cannabis extracts and Marinol.
• Takes over an hour for Marinol to reach full effect.
• Dronabinol is a Schedule III controlled substance in the US.

Scientific Studies and Research:

• Investigated cannabinoid and terpene content in Cannabis sativa plants.
• Cannabinoid analgesia as a new therapeutic option for chronic pain treatment.
• Behavioral pharmacology studies on the effects of Dronabinol.
• Research on the sedative activity of cannabis and its cannabinoid content.
• Dronabinol drug labels and data available through the U.S. National Library of Medicine.

Public Perception and Media Coverage:

• Media reports on the use of Dronabinol in medical treatments.
• Discussions on constitutional aspects of marijuana laws involving doctor testimonies.
• Controversies surrounding medicinal marijuana.
• Highlighted potential therapeutic benefits of Dronabinol.
• Government actions and decisions on Dronabinol regulation in the media.

Dronabinol Data Sources